The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels

Angiogenesis

Volumn 7, Issue 3, 2004, Pages 225-233

  Osusky, Katherine L ^a   Hallahan, Dennis E ^a,b,c   Fu, Allie ^a   Ye, Fei ^e   Shyr, Yu ^c   Geng, Ling ^a,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e NONE

Author keywords

Angiogenesis; HUVEC; LLC; Metastasis; SU11248

Indexed keywords

RECEPTOR BLOCKING AGENT; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR INHIBITOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DOPPLER FLOWMETRY; HUMAN; HUMAN CELL; LUNG CARCINOMA; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BLOOD VESSELS; CARCINOMA, LEWIS LUNG; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECURRENCE; UMBILICAL CORD;

ANIMALIA;

EID: 12444297983     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-004-3149-y     Document Type: Article

References (39)

1. Kerbel RS. Tumor angionesis: past, present, and near future. Carcinogenisis 2000; 1(3): 2505-515.
2. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 1977; 14: 53-65.
3. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43:175-203.
4. Bos R, Zhong H, Hanrahan CF Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001; 93: 309-14.
5. Giatromanolaki A, Koukourakis MI, Sivridis E et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 2001; 85: 881-90.
6. Nakayama K, Kanzaki A, Hata K et al. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett 2002; 176: 215-23.
7. Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997; 94: 8104-9.
8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
9. Richard DE, Berra E, Pouyssegur J. Angiogenesis: How a tumor adapts to hypoxia. Biochem Biophys Res Commun 1999; 266(3): 718-22.
10. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48-50.
11. Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8.
12. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002; 29: 3-9.
13. Ferrara N, Gerber HP, LeCouter J. The Biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
14. Inoue K, Slaton JW, Karashima T et al. The prognostic valie of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000; 6: 4866-73.
15. Niedergethmann M, Hildrenbrand R, Wostbrook B et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002; 25: 122-9.
16. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 407-24.
17. Bergers G, Javaherian K, Lo KM et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808-12.
18. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999; 56: 794-814.
19. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-8.
20. Annie T, Fong T, Laura K et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor(Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
21. Mendel DB, Laird AD, Smolich BD et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anti-Cancer Drug Design 2000; 15: 29-41.
22. Schueneman AJ, Himmelfarb E, Geng L et al. SU11248 Maintenance therapy prevents tumor regrowth after fractioned irradiation of murine tumor models. Cancer Res 2003; 63: 4009-16.
23. Sun L, Tran N, Tang F et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectively toward particular receptor tyrosine kinases. J Med Chem 1998; 41: 2588-603.
24. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37.
25. Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at Ser-1177 is required for VEGF-induced endothelial cell migration. FEBS 2000; 477: 258-62.
26. Sonveaux P, Brouet A, Havaux X et al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: Implications for tumor radiatherapy. Cancer Research 2003; 63: 1012-19.
27. Kureishi Y, Luo Z, Shiojima I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-10.
28. Abdollahi A, Lipson KE, Han X et al. SU5416 and SU6668 Attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003; 63: 3755-63.
29. Geng L, Donnelly E, McMahon G et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001; 61: 2413-19.
30. Kilic T, Alberta JA, Zdunek PR et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Research 2000; 60: 5143-50.
31. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-8.
32. Camphausen K, Moses MA, Beecken WD et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001; 61: 2207-11.
33. Shibuya M, Yamaguchi S, Yamane A et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5: 519-24.
34. Terman BI, Carrion ME, Kovacs E et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991; 6: 1677-83.
35. de Vries C, Escobedo JA, Ueno H et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-91.
36. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
37. LeCouter J, Lin R, Ferrara N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 2002; 8: 913-7.
38. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.
39. Asahara T, Chen D, Takashi T et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998; 83(3): 233-40.